Ion Beam Applications Sa · EURONEXT:IBAB
Ion Beam Applications Sa — Investor Day (September 2017)
119 slides from Ion Beam Applications Sa's investor day presentation, Sep 25, 2017
Slide 1: Capital Market Day
Capital Market Day Olivier Legrain (CEO) 25 September 2017 © 2017 IBA SA
Slide 2: Agenda
Agenda Introduction Olivier Legrain, Chief Executive Officer, IBA The role on proton therapy in oncology Andrew K. Lee, MD, MPH, Medical Director, Texas Center for Proton Therapy Testimony on the development of a state-of-the-art proton therapy center Craig W. Stevens, MD, PhD, Chair of Radiation On
Slide 3: Disclaimer
Disclaimer This presentation may contain forward-looking statements concerning industry outlook, including growth drivers; the company’s future orders, revenues, backlog, or earnings growth; future financial results; market acceptance of or transition to new products or technology and any statements
Slide 4: In the US, 1.1M patients receive radiation therapy
In the US, 1.1M patients receive radiation therapy There are about 1.7M new cancer diagnoses per year in the US, and about 1.1M of patients receive radiation, often with curative intent 4
Slide 5: RT manufacturers capture a tiny slice of US Oncology market
RT manufacturers capture a tiny slice of US Oncology market Despite nearly 1M patients treated per year, often with curative intent, RT manufacturers capture a tiny slice of the US Oncology market 5
Slide 6: Proton therapy capacity gap - 2035
Proton therapy capacity gap - 2035 Estimation of RT and PT rooms needed by 2035 - Radiotherapy rooms needed by 2035 estimated by Lancet Oncology - www.thelancet.com/oncology - ProtonTherapy rooms needed by 2035 extrapolated worldwide from the “Horizon Scanning : Proton Therapy “in the Netherlands ht
Slide 7: Proton therapy capacity gap - today
Proton therapy capacity gap - today 7 Source : IBA internal modeling based on Model Based Approach developed in The Netherlands (https://www.gezondheidsraad.nl/sites/default/files/proton%20radiotherapy200917E_0.pdf)
Slide 8: Proton therapy catalysts
Proton therapy catalysts Cost Increasing publications Innovations and new 1 efficient 2 and support 3 technologies Relative cost Guidelines ASTRO / NCCN Compact PT Publications Statistics per Year Adaptive PT Software Imaging Organ motion management Radiotherapy Surgery Chemotherapy Turn
Slide 9: Growing acceptance of proton therapy
Growing acceptance of proton therapy 108 Trials Open and Recruiting Publications Statistics per Year End December 2016 Number of publications up to end of 2016 Data from https://clinicaltrials.gov/ 99
Slide 10: Growing acceptance of proton therapy
Growing acceptance of proton therapy New guidelines further endorse proton therapy as an important treatment option in the fight against cancer American Society for Radiation Oncology National Comprehensive Cancer Network (ASTRO) (NCCN) 5 new indications in Group 1 5 new indications (frequ
Slide 11: IBA - a global leader in proton therapy
IBA - a global leader in proton therapy 11
Slide 12: IBA – a global leader in proton therapy
IBA – a global leader in proton therapy Oklahoma New Jersey 5 continents 20 countries 51 rooms in construction/ installation South Wales North East Thames Valley 62 rooms treating 12
Slide 13: Oklahoma, New Jersey, South Wales
Oklahoma New Jersey South Wales North East Thames Valley
Slide 14: IBA – a global leader in proton therapy
IBA – a global leader in proton therapy Global share of Share of installed base installed base in rooms in NA in rooms Share of Share of installed base installed base in in APAC in Europe and rooms ROW in rooms 14
Slide 15: IBA lead over competition
IBA lead over competition 15
Slide 16: Proteus ONE and Proteus PLUS
Proteus ONE IBA world-class innovative proton therapy solutions Proteus PLUS
Slide 17: Proteus ONE
Proteus ONE COMPACT Open Gantry & IMPT accelerator design Most precise treatments Easy Workflow INTEGRATED Software, Dosimetry & Training 17
Slide 18: Proteus ONE
Proteus ONE PROVEN PENCIL BEAM SCANNING For highly conformal IMPT INSTANT 2D & CONE- BEAM CT For Image-Guided PT PATIENT AND STAFF FRIENDLY Open environment 18
Slide 19: Proteus PLUS
Proteus PLUS Research room Fixed Beam Treatment Full Gantry control room Machine & Patient QA Treatment planning room 19
Slide 20: IBA lead over competition
IBA lead over competition Fastest from contract to patient treatment Largest software integration Best IMPT System Best image guided Unique value in the system industry Best workflow 20 IBA CONFIDENTIAL
Slide 21: IBA lead over competition: largest software integration
IBA lead over competition RayStat. Largest Software integration RayCare Monaco Eclipse Xio Aria Mosaiq RayStat. RayStat. Eclipse Pinnacle IBA CONFIDENTIAL
Slide 22: Elekta and IBA agree on a comprehensive partnership
Elekta and IBA agree on a comprehensive partnership Co-funding for all PT related software development MOSAIQ and Monaco Competitive bundling of PT/Linac/SW vs competition Commercial collaboration finder’s fee globally for PT deals Elekta initiate finder’s fee globally for Elekta linac d
Slide 23: Fastest from contract to patient treatment
IBA lead over competition Fastest from Contract to Patient treatment IBA building 14 months | equipment 12 months Competitor 1 building 23 months | equipment 19 months Competition 2 building 22 months | equipment 22 months IBA CONFIDENTIAL
Slide 24: Best IMPT System
IBA lead over competition Best IMPT System Features Customer gain IBA Competitor 1 Competitor 2 Beam availability Best treatment quality < 1s 3s 5s Room matching Best treatment quality < 1% < 3% < 5% Best throughput Room switching time < 10s < 30s < 45s Patient confort Minimum range Best conformity
Slide 25: Best Image Guided System
IBA lead over competition Best Image Guided System Features Customer gain IBA Competitor 1 Competitor 2 Best treatment quality X-Ray direction VS beam direction BEV 45° 45° Best workflow In combination with BEV, faster and Orthogonal kV-kV Yes Yes Yes better setup CBCT LFOV Best imaging quality 50cm
Slide 26: Best Workflow
IBA lead over competition Best Workflow Features Customer gain IBA Competitor 1 Competitor 2 Reduced anesthesia for pediatrics, Ambient experience solution Yes No No best throughput More seamless operation, Wireless hand pendant more freedom of movement, Yes No No best throughput Most intuitive way
Slide 27: Unique Value in the Industry
IBA lead over competition Unique Value in the Industry IBA Competitor 1 Competitor 2 Features Upgradeability Proven at 10+ centers No proven track record No proven track record Open architecture Proven at 48 centers Optimized for own SW only Yes, limited experience Experience > 30 years in Proton Th
Slide 28: The future of proton therapy
The future of proton therapy 28
Slide 29: Largest and most experienced community in proton therapy
Largest and most experienced community in proton therapy 50 partners perfecting cancer care 29
Slide 30: IBA's worldwide research collaboration
IBA’s worldwide research collaboration Russia Clinical partners Federal High-Technology Center for Medical Radiology FMBA [RUS] North America Clinical partners Massachussets General Hospital Burr Proton Therapy center [US] University of Florida Health Proton Therapy Institute [US] University
Slide 31: The future of proton therapy
The future of proton therapy Irradiation in one Volumetric imaging breath hold for replanning Eye treatment On-Line QA in a Gantry On-Line adaptive 31 IBA CONFIDENTIAL 46
Slide 32: The future of personalized precision
The future of personalized precision Log-based Automated patient QA re-planning Anatomical changes Virtual CT Fast Irradiation Lung Motion Prompt Gamma H&N Reduction Breast Pediatrics Proton Range Moving Online adaptive Radiography uncertainties targets workflow MR Guided Proton Therapy Others 32 IB
Slide 33: API based architecture to be fast and flexible
API based architecture to be fast and flexible Service QA Treatment Session Manager manages adaptive workflows in the PT treatment room Proteus Research CLASS OIS TPS 33 IBA CONFIDENTIAL
Slide 34: Strong worldwide pipeline
Strong worldwide pipeline 654 Leads 100 Qualified leads 50 Closing(24 months) IBA global leads 34
Slide 35: Our strategy is to create a virtuous circle in PT
Our strategy is to create a virtuous circle in PT Enhance market penetration Develop regionalization Leverage partnership Strengthen Market Leadership PARTNERSHIPS Build clinical Increase clinical relevance & cost Reduce cost of modality advantage Accelerate PT adoption Invest in clinica
Slide 36: The role on proton therapy in oncology
The role on proton therapy in oncology Andrew K. Lee, MD, MPH, Medical Director, Texas Center for Proton Therapy © 2017 IBA SA
Slide 37: The role of proton therapy in oncology and future evolution
The role of proton therapy in oncology and future evolution Andrew K. Lee, M.D., MPH Medical Director Texas Center for Proton Therapy
Slide 38: Clinical benefits of proton therapy
Clinical benefits of proton therapy Higher radiation doses to tumor Minimizes dose to normal tissues Better tumor control Decreased side effects: early and late Preserve organ function Better tolerance of multi-modality therapy e.g. Chemotherapy and/or surgery “One cannot have a radiatio
Slide 39: What cases to consider for protons therapy?
What cases to consider for protons therapy? Pediatric Adults w/ projected longevity >20 years Primary CNS Skull base Para-nasal sinus Nasopharynx Oropharynx (especially younger HPV+) Left-sided breast + lymphatics Anterior/Posterior mediastinum Lymphoma NSCLC (stage II-III, non-operative) Distal eso
Slide 40: Proton Rx: Advances and future directions
Proton Rx: Advances and future directions Pencil beam scanning Intensity modulated proton therapy Better treatment planning software PBS with apertures for sharper edges Smaller (and less expensive) proton units On-board volumetric imaging (CBCT) Advances in technology have expanded clinical indicat
Slide 41: How are protons different from X-rays?
How are protons different from X-rays?
Slide 42: Proton is hydrogen atom without electron
Proton is hydrogen atom without electron (Heavy particle) Electron Proton 6
Slide 43: Protons are accelerated to almost light speed for treatment
Protons are accelerated to almost light speed for treatment Hyper-speed protons are used like “smart bullets” to kill cancer cells. 7
Slide 44: Key components
Key components Gantry Cyclotron Giant gantries provide Using electric fields, the the beam pathway to cyclotron can accelerate treatment nozzle, utilizing hydrogen protons to two- series of steering and thirds the speed of light. focusing magnets. Patient Electromagnets Magnets focus and steer proto
Slide 45: Gantry diameter and weight
Diameter ~ 33 feet Weight >100 tons (equivalent to Boeing 757 with passengers and cargo) 9
Slide 46: What patient sees
What patient sees Nozzle kV imagers IGRT, CBCT Snout Screens Pendant Robotic couch 10
Slide 47: Single room units are a fraction of cost of multi-room centers
Single room units are a fraction of cost of multi-room centers but… Typically partial gantries & not as cost-effective if > 2 rooms 11
Slide 48: X-rays pass through tissue. Protons STOP
X-rays pass through tissue. Protons STOP EXTRA RADIATION Beam EXTRA RADIATION 12
Slide 49: Protons vs X-rays exit dose
X-RAYS PROTONS Tumor NO Exit dose Exit dose 100% dose 40% dose Exit dose NO exit dose 13
Slide 50: Medulloblastoma
Medulloblastoma Exit dose ~ 50% No exit dose X-rays Protons
Slide 51: IMRT or Protons?
IMRT or Protons? Or Gamma Knife Or Cyber Knife All Or Tomo Therapy X-rays Or True Beam
Slide 52: IMRT vs. Protons
IMRT vs. Protons : Maximize tumor dose conformity and minimize normal tissue exposure TUMOR TUMOR High dose radiation cloud High dose radiation cloud Low Dose Radiation Cloud Low Dose Radiation Cloud Traditional 2D/3D RT 16 IMRT Protons
Slide 53: Prostate cancer
Prostate cancer Unnecessary IMRT Protons radiation with IMRT * 25 Gy (25 Sv) of Unnecessary Radiation = 2,500 20,833 25,000x 1.83x Pelvic CTs Pelvic X-Rays General Public Additional (10 mSv) (1.2 mSv) Annual Limit Cancer Risk* (1.0 mSv) (CTs, 65 yo) Source: Matt Palmer 17 * http://www.xrayrisk.com/c
Slide 54: Longer waits result in more second cancers
Longer waits result in more second cancers Latency 5-9 years Latency 10-14 years Latency ≥15 years p-trend Oral/pharynx 1.12 (0.99 to 1.27) 1.14 (0.95 to 1.38) 0.95 (0.74 to 1.22) 0.34 Rectum* 1.13 (0.94 to 1.35) 1.33 (1.03 to 1.70) 0.91 (0.64 to 1.27) 0.54 Larynx 1.57 (1.08 to 2.36) 1.04 (0.66 to 1
Slide 55: Types of proton therapy delivery
Types of proton therapy delivery Passive scattered (most common) Spot-scanning (pencil-beam scanning) Intensity modulated proton therapy (IMPT) 19
Slide 56: Spot scanning (pencil-beam scanning)
Spot scanning (pencil-beam scanning) 20
Slide 57: Conventional proton therapy
“Conventional” proton therapy (Right lateral beam’s eye view) Target 21
Slide 58: The pencil-beam scanning mode of proton beam delivery
The pencil-beam scanning mode of proton beam delivery 22 Source: A Smith. Med. Phys. 2009
Slide 59: 23
23
Slide 60: Proton therapy in 1980's vs. Modern era
Proton therapy in 1980’s vs. Modern era 24 Journal of Urology 167:123, 2002
Slide 61: Randomized trials between IMRT vs. Protons should use PBS
Any randomized trials between IMRT vs. Protons should be done with PBS (IMPT) 2D 3D IMRT CONVENTIONAL IMPT PROTONS Intensity X-rays X-rays (Passive-scattered) modulated proton therapy Conformity + ++ ++++ +++1/2 ++++ Normal +++ +++ ++++ ++ ++ tissue exposure Highly conformal but less tissue exposure
Slide 62: How can pencil beam scanning expand clinical utility?
Beyond tumor sites like CNS & HN, how can pencil beam scanning proton therapy (IMPT) expand the clinical utility of proton therapy?
Slide 63: Breast + lymph nodes w/ pencil-beam proton therapy
Breast + lymph nodes w/ pencil-beam proton therapy Coronal Axial 27
Slide 64: For breast cancer, linear risk of coronary events
For breast cancer, linear risk of coronary events… 7.4% increase per mean Gy to heart Darby et al. NEJM 2013;368. 28
Slide 65: Proton therapy for lung cancer represents particular challenge
Proton therapy for lung cancer represents particular challenge (e.g. moving target, density changes, etc) PROTON ADVANCES IN LUNG CANCER Better target delineation Management of respiratory motion On-board image guidance (CBCT) Better treatment planning techniques Better delivery techniques Understan
Slide 66: Anterior tumors (e.g. lung, thymoma, lymphoma)
Anterior tumors (e.g. lung, thymoma, lymphoma) 30
Slide 67: Protons can keep dose anteriorly
Protons can keep dose anteriorly 31
Slide 68: Same risk for Hodgkin lymphoma survivors
Same risk for Hodgkin lymphoma survivors 32 F. Van Nimwegen et al. J Clin Oncol 2015;34
Slide 69: Case example: Advanced NSCLC
As systemic therapy improves, so must local- regional Rx…Case example: Advanced NSCLC 59 yo woman w/ stage IIIB NSCLC (T1N3, ALK +) RLL primary with extensive bilateral mediastinal, hilar, S/C disease Neaoadjuvant chemoRx and crizotinib Good metabolic response but gross residual disease Pl
Slide 70: Axial Comparison
Axial Comparison Protons Photons (IMRT) Dark Blue 60 GyE Yellow 30 GyE Gold 15 GyE The Proton plan spares more normal LUNG than the IMRT plan 34
Slide 71: Coronal Comparison
Coronal Comparison Protons Photons (IMRT) Dark Blue 60 GyE Yellow 30 GyE Gold 15 GyE 35
Slide 72: RTOG 0617 Overall survival multivariable analysis
RTOG 0617 Overall survival multivariable analysis Heart dose was independent factor Potential to improve survival with particle therapy by reducing cardiac doses Courtesy of Dr. Stephen Chun. J Clin Oncol 34, 2016 36
Slide 73: Lymphopenia association with tumor volume and lung dose
ee Lymphopenia Association With Gross Tumor Radiation Oncology Volume and(Lung V5 and Its Effects on Non-Small Cell Lung Cancer Patient Outcomes Chad Tang, MD, MS,* Zhongxing Liao, MD,* Daniel Gomez, MD,* Absolute Lymphocyte Count Lawrence Levy,,-MS,* Yan Zhuang, MD,* Rediet A. Gebremichael, BS,* 94
Slide 74: Esophageal Cancer
Esophageal Cancer Protons IMRT 38
Slide 75: Improved perioperative pulmonary complications with proton therapy
Improved perioperative pulmonary complications with proton therapy 39 Source: Wang J, Lin SH, et al. Int J Radiat Oncol Biol Phys 2013
Slide 76: Value of proton therapy in esophageal cancer
Value of proton therapy in esophageal cancer Protons reduces average hospital stay by > 2 days and max hospital days 40 Source: Lin SH et al., ASTRO 2015
Slide 77: Proton vs X-Ray therapy comparison
Proton X-Ray Added Radiation Therapy (IMPT) Therapy (IMRT) with X-Rays 41
Slide 78: Value Proposition- Head and Neck Cancer
Value Proposition- Head and Neck Cancer Equivalent at 21 Days Thaker N et al. Oncology Payers 2014
Slide 79: What is "new" in proton therapy?
What is “new” in proton therapy? Proton therapy has improved as technology has advanced (just like X-ray therapy) Imaging (OBI and CBCT) Treatment planning (software) Treatment delivery systems Intensity modulation Immobilization 43
Slide 80: THANK YOU
THANK YOU Andrew.Lee@USOncology.com TexasCenterForProtonTherapy.com
Slide 81: Development of a state-of-the-art proton therapy center
Development of a state-of-the-art proton therapy center Craig W. Stevens, MD, PhD, Chair of Radiation Oncology, Beaumont Health System © 2017 IBA SA
Slide 82: Beaumont Proton Therapy Center
CONFIDENTIAL Beaumont Proton Therapy Center Craig W. Stevens, M.D., Ph.D. Professor and Chair Department of Radiation Oncology
Slide 83: Thanks!
Thanks! • IBA • Team at Beaumont – Too many people to count but – Xuanfeng Ding, PhD – Peyman Kabolizadeh, MD PhD – Tom Lanni – Patti Cardoze 9/26/2017 CONFIDENTIAL
Slide 84: Summary
Summary • We successfully installed and commissioned the first proton center in MI • We met critical C.O.N. timeline requirements • This allowed us to – Treat the first proton patient in MI – Increase our overall consults by almost 10% – Treat the first pediatric patient with protons in MI • Impossi
Slide 85: Beaumont Proton Therapy Center
Beaumont Proton Therapy Center
Slide 86: Physics of Proton Therapy
Physics of Proton Therapy • Photons • Protons BODY BODY ORGAN ORGAN TUMOR TUMOR ORGAN ORGAN
Slide 87: Disease sites
Disease sites Less integral dose
Slide 88: For Pediatric patient
For Pediatric patient Photon VMAT Proton PBS
Slide 89: Beaumont Journey
Beaumont Journey • Initial plan for Proton Center dates from ~2007 – The 5 room plan was tabled due to the financial crisis • When I was being recruited to Beaumont in 2013, PTC was reintroduced. • Board approval in January of 2014 • CON requirements were daunting – CON commission had NEVER overseen
Slide 90: CON Requirements
CON Requirements 9/26/2017 CONFIDENTIAL
Slide 91: Beaumont Journey
Beaumont Journey • Request for Proposals Drafted – With help from Proton International – IMPT, CBCT, FDA approved, install by March 2017 • Sent to 7 vendors – 6 responded • Three vendors were chosen for site visit – One couldn’t deliver IMPT – One had a compact cyclotron that would reduce the cost o
Slide 92: CON Requirements
CON Requirements 9/26/2017 CONFIDENTIAL
Slide 93: Beaumont Journey
Beaumont Journey • In November 2016, clear we would miss the last two milestones – One because it was never reasonable – One because of weather and other construction delays • We restated the time line with a plan to treat the first patient by June 30, 2017 9/26/2017 CONFIDENTIAL
Slide 94: Beaumont Journey
Beaumont Journey • In February 2017, the schedule slipped again • We reached out to IBA and other partners to develop an aggressive new schedule • Plan for first patient to be a patient with a brain tumor 9/26/2017 CONFIDENTIAL
Slide 95: Collaborate and synchronize the team schedule
Collaborate and synchronize the team schedule • Combine the beam data acquisition procedure with acceptance test (IBA & Beaumont) • Lock beam optics settings • Beam modeling and validations (Beaumont & RaySearch America & Sweden) • Dry run with current data format • Communicate with the RaySearch te
Slide 96: Beaumont Commissioning Timeline
Beaumont Commissioning Timeline (Double shifts) (Double shifts) Ding et al. NA-PTCOG 2017 9/26/2017 52
Slide 97: Slide 97
Slide 98: Protons
Protons Beaumont Proton Therapy Center
Slide 99: Slide 99
Slide 100: ProteusONE treatment room
ProteusONE treatment room 220 degree Compact Gantry Superconducting Synchrocyclotron Stereotactic imaging system Pencil Beam Scanning Technique And CBCT Phillips Ambience light system 6 degree robotic couch Rolling floor
Slide 101: Lobby, Treatment Room, Exam Room
Lobby Treatment Room Exam Room
Slide 102: Protons
Protons • Our center has IMPT and 3 options for daily imaging – Very precise delivery of dose to tumor – Reduce uncertainties, and so reduce the target volume – This further reduces normal tissue doses – Better dose to tumor with less side effects!!! • Pediatric Oncology relocated to second floor of
Slide 103: Proton Center 1st Patient Treatment June 28, 2017
CONFIDENTIAL Proton Center 1st Patient Treatment June 28, 2017
Slide 104: Treatment mix
Treatment mix Case Mix - In Treatment 2,5 2 2 2 2 1,5 1 1 1 1 1 1 0,5 0 9/26/2017 CONFIDENTIAL
Slide 105: Beaumont Proton Therapy Center
Beaumont Proton Therapy Center Commissioning continues……. • CNS – done • Tumors with stable soft tissue component - done – Sarcomas – Prostate • Tumors without stable soft tissue component – mostly done – Immobile lung cancers- done – Chest wall – almost done – H&N – almost done • Anesthesia – Novem
Slide 106: During this time we also
During this time we also • Dr. Ding has developed a process for rotational IMPT with PBS – SParc • Developed a sponsored research program with IBA • Submitted R03 for technology development • Published extensively • Developed and opened a Patient Access Center to facilitate referrals and coordinate
Slide 107: Summary
Summary • We successfully installed and commissioned the first proton center in MI • We met critical C.O.N. timeline requirements • This allowed us to – Treat the first proton patient in MI – Increase our overall consults by almost 10% – Treat the first pediatric patient with protons in MI • Impossi
Slide 108: Questions?
Questions? 9/26/2017 64
Slide 109: Slide 109
Slide 110: North American Market Dynamics
North American Market Dynamics Beth Klein - Executive Vice President, IBA North America © 2017 IBA SA
Slide 111: PT market dynamics in North America
PT market dynamics in North America Softer near term market Chapter 11 concerns Reimbursement/Payor uncertainties still exist Competitive dynamics resulting in more aggressive pricing NA predicted to grow to 46 centers by 2020 More centers opening, strong pipeline Wider acceptance of PT, NCCN / ASTR
Slide 112: Strong IBA North America market leadership position
Strong IBA North America market leadership position Share of installed base in NA in rooms 68
Slide 113: Newest additions to IBA's league of PT experts
Newest additions to IBA’s league of PT experts 69
Slide 114: North American headquarters – Reston VA
North American headquarters – Reston VA Proton Therapy functions co-located in Reston: Sales & Marketing Sales support Product specialists Project management Install seams Service delivery Operations Finance EHS, Legal, Information Technology >250 PT Experts focused on serving our
Slide 115: Value of IBA's experience
Value of IBA’s experience 98% Clinical Availability Smooth Impact Operation Fastest 30+ Fastest Throughput Years Install/Ramp-up Security of Improved Proven Investment Upgradability ROI 71
Slide 116: IBA's unique value in the industry
IBA’s unique value in the industry Features IBA Upgradeability Proven at 10+ centers Open architecture Proven at 48 centers Experience > 30 years in Proton Therapy > 250 trained and certified service engineers in Size and depth of the service organization USA Motion management solutions Multiple sol
Slide 117: Conclusion
Conclusion Olivier Legrain, Chief Executive Officer, IBA © 2017 IBA SA
Slide 118: Conclusion
Conclusion Strong perspectives for the proton therapy market Growing acceptance of proton therapy Increasing amount of scientific data Recent update of ASTRO and NCCN guidelines Strong pipeline IBA technological lead over competition IBA world-class innovative proton therapy solutions
Slide 119: Question and Answer
Question and Answer
Ion Beam Applications SA (IBA) — Investor Day (September 2017) on 6ix